FTC Takes Action to Protect Americans from Higher Drug Costs in Aurobindo, Lannett Deal

The Federal Trade Commission intervened in the $250 million acquisition of Lannett Company Inc. by Aurobindo Pharma Limited to protect American patients from higher drug costs. To resolve anticompetitive concerns, the proposed FTC order requires Aurobindo Pharma Limited to divest four different generic drug products. This action ensures that the merger does not lead to increased prices for consumers, maintaining competition in the generic drug market as a condition for completing the pharmaceutical company acquisition.